SA
BIO icon

Strategic Advocates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Strategic Advocates’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17K Hold
4
– – ﹤0.01% 222
2026
Q1 		$1.11K Hold
4
– – ﹤0.01% 231
2025
Q4 		$1.22K Hold
4
– – ﹤0.01% 508
2025
Q3 		$1.12K Buy
+4
New +$1.09K ﹤0.01% 496

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Strategic Advocates's BIO Position: Q2 2026 in Review

Strategic Advocates held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 4 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #222.

Strategic Advocates first reported a position in BIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.22K in Q4 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Strategic Advocates held 4 shares of Bio-Rad Laboratories Class A worth $1.17K as of Q2 2026.
  • Strategic Advocates left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Strategic Advocates's portfolio in Q2 2026, its #222 holding.
  • Strategic Advocates first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 4 quarters since.
  • Strategic Advocates's Bio-Rad Laboratories Class A position peaked at $1.22K in Q4 2025.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.